Our results support a role for the MALAT1-BRF2 regulatory axis in HCC and suggest that targeted inhibition of MALAT1 by ASO technology may be an effective therapeutic approach to delay HCC progression. Here, BRF2 is linked to hepatocellular carcinoma.